The premenopausal and postmenopausal women were matched for BMI, WC, and prevalence of overweight, obesity, central obesity, smoking, and low physical activity (Table 1).
However, in this study these indicators of body mass did not significantly affect the difference in the A-FABP concentration because both groups were matched for BMI, WC, and the prevalence of overweight and obesity.
Both groups were matched for age, body mass index (BMI), prevalence of diabetes mellitus, serum creatinine, Euroscore, aortic cross clamp and cardiopulmonary bypass time, and total length of anesthesia.
Although we observed that EDSS at last follow-up was slightly higher in the biopsy cohort compared with the multiple sclerosis prevalence cohort when matched for disease durations between 0 5 and 5 10 years, it is well recognized that EDSS scores in the low range are less reproducible and a 1 point increase in EDSS when <4 is of lesser clinical importance than a 1 point rise in EDSS ≥6.
Every subject with diabetic foot was matched for age (± 3 years), sex, and cardiovascular risk factor prevalence with one control subject.
Interestingly, although matched for age and gender, women with RA had a higher prevalence of menopause than women in the control group.
Controls were matched for gender.
Patients with diabetes had a higher prevalence of dyslipidaemia, a higher prevalence of hypertension (despite attempts at matching for hypertension) and a higher BMI, compared to patients without diabetes.
Following this same methodology, we developed classifications for FMI by selecting values for FMI that matched the population prevalence of the WHO BMI classifications [14] in young adults at age 25.
Findings from published studies from various Western European countries generally match the prevalence reports for the 3 major psychotropic classes (stimulants, antidepressants and antipsychotics) in Germany and the Netherlands as detailed below.
